| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
86,568,000 |
| Market
Cap: |
1.26(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.79 - $20.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
6,611,050 |
8,088,052 |
| Total Buy Value |
$0 |
$0 |
$45,289,581 |
$53,421,765 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
4 |
9 |
| Total Shares Sold |
26,110 |
103,816 |
107,114 |
108,208 |
| Total Sell Value |
$411,056 |
$1,780,570 |
$1,802,142 |
$1,812,515 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
5 |
12 |
14 |
15 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nashat Amir |
|
– • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
I/I |
197,711 |
548 |
|
- |
|
| Myles Edward H |
COO & CFO |
• – – |
2023-12-07 |
4 |
AS |
$17.53 |
$436,820 |
D/D |
(24,914) |
168,784 |
|
-21% |
|
| Myles Edward H |
COO & CFO |
• – – |
2023-12-07 |
4 |
OE |
$4.86 |
$121,082 |
D/D |
24,914 |
193,698 |
|
- |
|
| Nashat Amir |
|
– • – |
2023-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
13,133 |
20,574 |
|
- |
|
| Nashat Amir |
|
– • – |
2023-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(598,537) |
0 |
|
- |
|
| Nashat Amir |
|
– • – |
2023-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
98,859 |
276 |
|
- |
|
| Samsara Biocapital, L.p. |
10% Owner |
– – • |
2023-10-16 |
4 |
B |
$6.85 |
$15,000,000 |
I/I |
2,189,781 |
6,788,609 |
1.5 |
92% |
|
| Akkaraju Srinivas |
Director |
– • • |
2023-10-16 |
4 |
B |
$6.85 |
$15,000,000 |
I/I |
2,189,781 |
6,788,609 |
2.25 |
92% |
|
| Invus Public Equities Advisors, Llc |
|
– – • |
2023-10-12 |
4 |
B |
$6.85 |
$15,086,736 |
D/D |
2,199,931 |
11,259,438 |
0.01 |
94% |
|
| Qatanani Mo |
SVP AND HEAD OF RESEARCH |
• – – |
2023-09-18 |
4 |
S |
$6.34 |
$12,331 |
D/D |
(1,945) |
97,043 |
|
-134% |
|
| Parlavecchio Caryn |
CHRO |
• – – |
2023-08-16 |
4 |
S |
$6.83 |
$9,241 |
D/D |
(1,353) |
117,199 |
|
-182% |
|
| Qatanani Mo |
SVP and Head of Research |
• – – |
2023-06-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
104,800 |
|
14% |
|
| Parlavecchio Caryn |
CHRO |
• – – |
2023-06-21 |
4 |
D |
$8.75 |
$35,332 |
D/D |
(4,038) |
118,552 |
|
- |
|
| Ho Junlin |
GENERAL COUNSEL |
• – – |
2023-06-21 |
4 |
D |
$8.75 |
$38,027 |
D/D |
(4,346) |
158,591 |
|
- |
|
| Myles Edward H |
COO & CFO |
• – – |
2023-06-21 |
4 |
D |
$8.75 |
$62,456 |
D/D |
(7,138) |
203,791 |
|
- |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-04-28 |
4 |
B |
$6.43 |
$202,845 |
D/D |
31,557 |
9,059,507 |
2.45 |
-2% |
|
| Backstrom Jay T. |
CHIEF EXECUTIVE OFFICER |
• – – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
|
- |
|
| Myles Edward H |
COO & CFO |
• – – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
63,750 |
210,929 |
|
- |
|
| Ho Junlin |
GENERAL COUNSEL |
• – – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
46,875 |
162,937 |
|
- |
|
| Parlavecchio Caryn |
CHRO |
• – – |
2023-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
46,875 |
122,590 |
|
- |
|
| Ho Junlin |
GENERAL COUNSEL |
• – – |
2023-01-17 |
4 |
D |
$11.29 |
$51,125 |
D/D |
(4,529) |
116,062 |
|
- |
|
| Myles Edward H |
COO & CFO |
• – – |
2023-01-17 |
4 |
D |
$11.29 |
$79,503 |
D/D |
(7,043) |
147,179 |
|
- |
|
| Parlavecchio Caryn |
CHRO |
• – – |
2023-01-17 |
4 |
D |
$11.28 |
$33,096 |
D/D |
(2,934) |
75,715 |
|
- |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-01-09 |
4 |
S |
$9.48 |
$10,373 |
D/D |
(1,094) |
9,027,950 |
|
17% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-01-05 |
4 |
B |
$9.33 |
$455,091 |
D/D |
48,774 |
9,029,044 |
2.45 |
-12% |
|
119 Records found
|
|
Page 2 of 5 |
|
|
0.57 (4.08%) 
